Gut Protein Discovery Could Revolutionize Medicine

Scientists working in a laboratory with microscopes and test tubes

MIT scientists uncovered a gut protein that not only traps and kills antibiotic-resistant superbugs but also fortifies your body’s natural mucus shield—could this end the era of failing antibiotics?

Story Highlights

Intelectin-2 binds bacterial sugars to trap and disintegrate pathogens like Staphylococcus aureus and Klebsiella pneumoniae.
The protein crosslinks mucins, strengthening the GI tract’s protective mucus barrier against invasions.
Published March 16, 2026, in Nature Communications, led by MIT’s Laura Kiessling.
Offers broad-spectrum defense without targeting specific bacteria, unlike traditional antibiotics.
Potential breakthrough for IBD treatments and combating global antibiotic resistance.

Intelectin-2’s Dual Antimicrobial Mechanism

MIT researchers identified intelectin-2, a lectin protein in the gastrointestinal tract. This protein binds sugar molecules on bacterial cell membranes. It traps harmful bacteria, including resistant strains such as Staphylococcus aureus and Klebsiella pneumoniae. Experiments showed intelectin-2 slows bacterial growth and induces disintegration. This direct neutralization occurs without relying on narrow-spectrum antibiotics.

The protein’s action targets glycan motifs unique to pathogens. Biochemical assays confirmed binding specificity. Intelectin-2 distinguishes dangerous microbes from harmless ones. This selectivity enhances gut defense precision. Researchers demonstrated its efficacy against multiple GI pathogens in lab tests.

Reinforcing the Gut’s Mucus Barrier

Intelectin-2 crosslinks mucin components in the GI mucus layer. This reinforcement prevents pathogen penetration into intestinal walls. Mucus imbalances contribute to inflammatory bowel disease vulnerability. The protein stabilizes the barrier, addressing a key failure in IBD patients. MIT’s study provides direct evidence of this structural role.

Prior lectin research established mucosal defense basics. Intelectin-2’s dual function—antimicrobial and structural—fills critical gaps. The GI tract relies on this mucus shield daily. Weakened barriers invite infections amid rising resistance. This discovery leverages innate human biology over synthetic drugs.

Research Team and Publication Details

Laura Kiessling, Novartis Professor of Chemistry at MIT, served as senior author. Amanda Dugan and Deepsing Syangtan led experiments as former research scientist and PhD student. Contributors included Charles Bevins from UC Davis and Ramnik Xavier from Harvard and Broad Institute. MIT hosted the primary work. The team published findings March 16, 2026, in Nature Communications.

Kiessling stated intelectin-2 operates in complementary ways to stabilize mucus and neutralize bacteria. She emphasized harnessing human lectins as a new strategy against resistance. The study built on lectin biology through targeted assays. Collaborations amplified expertise in microbiology and genomics. Publication amplifies potential therapeutic pathways.

Therapeutic Potential for IBD and Resistance

Intelectin-2 positions as a biomarker and therapy target for IBD. Its broad efficacy bypasses antibiotic resistance mechanisms. Short-term validation aids diagnosis; long-term applications promise new antimicrobials. Patients with mucus defects stand to benefit most. Global resistance trends make this timely.

MIT scientists discover gut protein that traps and kills dangerous bacteria https://t.co/ipYfIvMh4m

— Un1v3rs0 Z3r0 (@Un1v3rs0Z3r0) March 16, 2026

Economic impacts include reduced costs for host-protein therapies versus new antibiotics. Social gains improve gut health outcomes for millions. Biotech shifts toward innate defenses accelerate gastroenterology innovations. Clinical timelines remain unstated, but data grounds optimism.